Al first ensured that the rats that underwent spinal cord injury demonstrated the proper level of debilitation
Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
These platforms typically offer online consultations with licensed prescribers who evaluate your health history, order necessary labs, and write prescriptions if appropriate
Semaglutide mimics the hormone GLP-1, which helps regulate appetite by signaling fullness to the brain, slowing stomach emptying, and improving insulin efficiency
Some patients find that morning administration rather than evening dosing helps, though there is no clinical evidence that timing significantly affects side effects